A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• NM Hahn, C Whalen, CJ Sweeney. Second-line pemetrexed (P) for the treatment of hormone refractory prostate cancer (HRPC): A Hoosier Oncology Group GU03-67. Preliminary analysis. Presented at the general poster session at the ASCO Annual Meeting, June 2-6, 2006, Atlanta, Georgia. J Clin Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 4644.
• NM Hahn, F Ademuyiwa, RT Zon, T Jones, W Dugan, C Whalen, M Yu, R Shanmugam, T Skaar, CJ Sweeney. A Multicenter Phase II Study of Pemetrexed for the Treatment of Hormone Refractory Prostate Cancer (HRPC) with Reduced Folate Carrier 1 (RFC1) Pharmacogenetic Analysis: GU03-67. Accepted to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL.

Manuscripts/Articles:

• NM Hahn, RT Zon, M Yu, FO Ademuyiwa, T Jones, W Dugan, C Whalen, R Shanmugam, T Skaar, CJ Sweeney. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Annals of Oncology 20: 1971–1976, 2009; doi:10.1093/annonc/mdp244; Published online 15 July 2009. See abstract.